€38.12
+2.88 (+8.17%)
EUR · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NANO.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339[Dose Escalation Part]: Determination of the Recommended DoseOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: NBTXR3, Nivolumab, Pembrolizumab · Radiation: SABR | Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder) | 145 | 2027-04-30 | in 252 d | 2025-10-24 |
| NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or OropharynxNCT01946867Dose Escalation: Incidence of DLTs and determination of the Recommended Phase 2 DoseOpen-label · Treatment | Not applicable | Unknown status | Device: NBTXR3 activated by IMRT | Head and Neck Cancer | 75 | Feb 2023 | — | 2022-12-29 |
| NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver CancersNCT02721056Determination of the Recommended Doses Toxicities (DLT)Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The RP2D for intratumoral injection was determined. With the changing practice of medicine for HCC, it was decided to design an independent Phase II clinical study. | Radiation: NBTXR3, IL or IA injection + SBRT | Liver Cancer | 23 | 2020-05-06actual | — | 2021-05-10 |
| NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate AdenocarcinomaNCT02805894Maximum Tolerated Dose and early Dose Limiting Toxicities (DLT) of NBTXR3Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape | Drug: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT | Prostate Cancer | 5 | 2020-03-19actual | — | 2021-05-10 |
| NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk WallNCT02379845Pathological Complete Response Rate (pCRR)Randomized · Open-label · Treatment | Phase 2/3 | Completed | Device: NBTXR3, Radiation therapy | Adult Soft Tissue Sarcoma | 180 | 2018-05-22actual | — | 2021-04-06 |
| NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the ExtremityNCT01433068Evaluation of the feasibility of the intratumor injection of NBTXR3Open-label · Treatment | Phase 1 | Completed | Device: NBTXR3 | Adult Soft Tissue Sarcoma | 22 | May 2014actual | — | 2020-10-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19